<DOC>
	<DOCNO>NCT00732121</DOCNO>
	<brief_summary>Background : Incretin hormone hormone produce gut response food intake . These hormone help body control metabolism glucose ( sugar ) . In particular , two incretin hormone ( GLP-1 GIP ) cause pancreas secrete insulin response high blood glucose level . This help body metabolize glucose effectively , lower blood sugar level . In addition effect pancreas , GLP-1 GIP effect tissue , include brain , gut , fat cell bone . A new class oral drug develop treatment type 2 diabetes mellitus ( T2DM ) call DPP-4 inhibitor increase level active form GLP-1 GIP body prevent breakdown . This study test whether medicine class call sitagliptin ( Januvia ) , commonly use treat T2DM , affect marker bone turnover patient T2DM . The hypothesis treatment sitagliptin increase marker bone formation decrease marker bone resorption mixed meal , enhance active circulating level GLP-1 , GIP GLP-2 . Methods : To address question recruit patient T2DM whose diabetes control either diet+exercise metformin ( another medicine commonly use treat T2DM ) . Subjects undergo measurement body fat bone mineral density DEXA scan 3-hour mixed meal test . During mixed meal test blood sample take measure much GLP-1 GIP produce . Markers bone formation also measure blood sample obtain mixed meal test . Subjects randomly assign 8 week treatment either sitagliptin ( 100 mg/day ) match placebo ( inactive tablet contain medication ) . Subjects see 4 week commence treatment ass safety tolerability . After 8 week treatment meal test repeat . Subjects wash initial treatment ( sitagliptin placebo ) 1 week ( , receive study medication period ) . After washout period , commence second 8-week period treatment study medication ( , receive sitagliptin initially , receive placebo period 2 vice-versa ) . At end period 2 , subject undergo third mixed meal test measurement GLP-1 , GIP markers bone turnover . Significance : Recent study suggest oral antidiabetic medication thiazolidinedione class , rosiglitazone ( Avandia ) pioglitazone ( Actos ) , may weaken bone , increase risk fracture old woman diabetes . The propose study test whether drug DPP-4 inhibitor class , sitagliptin ( Januvia ) , beneficial effect bone turnover increase activity GLP-1 GIP . Results pilot study may suggest need perform longer-term study determine whether DPP-4 inhibitor increase bone mineral density reduce risk fracture patient diabetes .</brief_summary>
	<brief_title>Bone Turnover Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes treat diet/exercise metformin HbA1c le equal 7 % Men woman age 4580 year old If female , must postmenopausal ( natural surgical ) Endocrine disorder ( acromegaly , anorexia , Cushings , type 2 diabetes , hyperparathyroidism , hyperthyroidism , hypercalcemia ) GI condition ( celiac sprue , gastric bypass/gastrectomy , active inflammatory bowel disease , cirrhosis ) Cancer ( include multiple myeloma ) within 3 year study ( except local nonmelanoma skin cancer cervical carcinoma situ ) Active alcoholism drug abuse Chronic kidney disease GFR &lt; 60 HIV/AIDS History hypersensitivity reaction sitagliptin DPP4 inhibitor Hemoglobin &lt; 12 mg/dL men &lt; 10 woman Taking medication could affect bone turnover ( estrogen , progesterone , testosterone , bisphosphonates , SERMS , calcitonin , teriparatide cyclosporine glucocorticoid , methotrexate phenothiazine ) , thiazolidinediones , sulfonylurea , dipeptidyl peptidase4 inhibitor , exenatide , insulin , weight loss drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>